{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:07:59Z","timestamp":1767139679738,"version":"build-2238731810"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T00:00:00Z","timestamp":1520812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T00:00:00Z","timestamp":1520812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s00415-018-8809-8","type":"journal-article","created":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T04:41:20Z","timestamp":1520829680000},"page":"80-85","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["RETRACTED ARTICLE: Meni\u00e8re\u2019s disease: combined pharmacotherapy with betahistine and the MAO-B inhibitor selegiline\u2014an observational study"],"prefix":"10.1007","volume":"265","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9544-2279","authenticated-orcid":false,"given":"Michael","family":"Strupp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludwig","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franz","family":"Schautzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Rujescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,12]]},"reference":[{"key":"8809_CR1","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1056\/NEJM198911163212004","volume":"321","author":"Parkinson Study Group","year":"1989","unstructured":"Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson\u2019s disease. N Engl J Med 321:1364\u20131371","journal-title":"N Engl J Med"},{"key":"8809_CR2","doi-asserted-by":"publisher","first-page":"h6816","DOI":"10.1136\/bmj.h6816","volume":"352","author":"C Adrion","year":"2016","unstructured":"Adrion C, Fischer CS, Wagner J, Gurkov R, Mansmann U, Strupp M (2016) Efficacy and safety of betahistine treatment in patients with Meniere\u2019s disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial). BMJ 352:h6816","journal-title":"BMJ"},{"key":"8809_CR3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1159\/000368293","volume":"20","author":"M Bertlich","year":"2015","unstructured":"Bertlich M, Ihler F, Freytag S, Weiss BG, Strupp M, Canis M (2015) Histaminergic H-heteroreceptors as a potential mediator of betahistine-induced increase in cochlear blood flow. Audiol Neurootol 20:283\u2013293","journal-title":"Audiol Neurootol"},{"key":"8809_CR4","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/1745-6215-15-328","volume":"15","author":"HG Bremer","year":"2014","unstructured":"Bremer HG, van Roy I, Pullens B, Colijn C, Stegeman I, van der Zaag-Loonen HJ, van Benthem PP, Klis SF, Grolman W, Bruintjes TD (2014) Intratympanic gentamicin treatment for Meniere\u2019s disease: a randomized, double-blind, placebo-controlled trial on dose efficacy\u2014results of a prematurely ended study. Trials 15:328","journal-title":"Trials"},{"key":"8809_CR5","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1080\/716689336","volume":"33","author":"XY Chen","year":"2003","unstructured":"Chen XY, Zhong DF, Duan JL, Yan BX (2003) LC-MS-MS analysis of 2-pyridylacetic acid, a major metabolite of betahistine: application to a pharmacokinetic study in healthy volunteers. Xenobiotica 33:1261\u20131271","journal-title":"Xenobiotica"},{"key":"8809_CR6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2174\/1871527316666170124165222","volume":"16","author":"L Dezsi","year":"2017","unstructured":"Dezsi L, Vecsei L (2017) Monoamine oxidase B inhibitors in Parkinson\u2019s disease. CNS Neurol Disord Drug Targets 16:425\u2013439","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"8809_CR7","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.2147\/DDDT.S120613","volume":"10","author":"MA El-Nabarawi","year":"2016","unstructured":"El-Nabarawi MA, Ali AA, Aboud HM, Hassan AH, Godah AH (2016) Transbuccal delivery of betahistine dihydrochloride from mucoadhesive tablets with a unidirectional drug flow: in vitro, ex vivo and in vivo evaluation. Drug Des Dev Ther 10:4031\u20134045","journal-title":"Drug Des Dev Ther"},{"key":"8809_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/BF00426954","volume":"57","author":"JD Elsworth","year":"1978","unstructured":"Elsworth JD, Glover V, Reynolds GP, Sandler M, Lees AJ, Phuapradit P, Shaw KM, Stern GM, Kumar P (1978) Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the \u2018cheese effect\u2019. Psychopharmacology 57:33\u201338","journal-title":"Psychopharmacology"},{"key":"8809_CR9","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1097\/MAO.0b013e31826dba83","volume":"33","author":"LM Fisher","year":"2012","unstructured":"Fisher LM, Derebery MJ, Friedman RA (2012) Oral steroid treatment for hearing improvement in Meniere\u2019s disease and endolymphatic hydrops. Otol Neurotol 33:1685\u20131691","journal-title":"Otol Neurotol"},{"key":"8809_CR10","doi-asserted-by":"publisher","first-page":"g6544","DOI":"10.1136\/bmj.g6544","volume":"349","author":"J Harcourt","year":"2014","unstructured":"Harcourt J, Barraclough K, Bronstein AM (2014) Meniere\u2019s disease. BMJ 349:g6544","journal-title":"BMJ"},{"key":"8809_CR11","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.colsurfb.2013.05.007","volume":"110","author":"RM Hathout","year":"2013","unstructured":"Hathout RM, Nasr M (2013) Transdermal delivery of betahistine hydrochloride using microemulsions: physical characterization, biophysical assessment, confocal imaging and permeation studies. Colloids Surf B Biointerfaces 110:254\u2013260","journal-title":"Colloids Surf B Biointerfaces"},{"key":"8809_CR12","doi-asserted-by":"publisher","first-page":"e39086","DOI":"10.1371\/journal.pone.0039086","volume":"7","author":"F Ihler","year":"2012","unstructured":"Ihler F, Bertlich M, Sharaf K, Strieth S, Strupp M, Canis M (2012) Betahistine exerts a dose-dependent effect on cochlear stria vascularis blood flow in guinea pigs in vivo. PLoS One 7:e39086","journal-title":"PLoS One"},{"key":"8809_CR13","doi-asserted-by":"publisher","unstructured":"James AL, Burton MJ (2001) Betahistine for Meni\u00e8re\u2019s disease or syndrome. Cochrane Database Syst Rev CD001873. https:\/\/doi.org\/10.1002\/14651858.CD001873","DOI":"10.1002\/14651858.CD001873"},{"key":"8809_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3233\/VES-130496","volume":"23","author":"M Lacour","year":"2013","unstructured":"Lacour M (2013) Betahistine treatment in managing vertigo and improving vestibular compensation: clarification. J Vestib Res 23:139\u2013151","journal-title":"J Vestib Res"},{"key":"8809_CR15","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/s00405-011-1647-2","volume":"268","author":"F Lezius","year":"2011","unstructured":"Lezius F, Adrion C, Mansmann U, Jahn K, Strupp M (2011) High-dosage betahistine dihydrochloride between 288 and 480\u00a0mg\/day in patients with severe Meniere\u2019s disease: a case series. Eur Arch Otorhinolaryngol 268:1237\u20131240","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"8809_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/VES-150549","volume":"25","author":"JA Lopez-Escamez","year":"2015","unstructured":"Lopez-Escamez JA, Carey J, Chung WH, Goebel JA, Magnusson M, Mandala M, Newman-Toker DE, Strupp M, Suzuki M, Trabalzini F, Bisdorff A (2015) Diagnostic criteria for Meniere\u2019s disease. J Vestib Res 25:1\u20137","journal-title":"J Vestib Res"},{"key":"8809_CR17","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s00405-015-3731-5","volume":"273","author":"MN Moller","year":"2016","unstructured":"Moller MN, Kirkeby S, Vikesa J, Nielsen FC, Caye-Thomasen P (2016) Expression of histamine receptors in the human endolymphatic sac: the molecular rationale for betahistine use in Menieres disease. Eur Arch Otorhinolaryngol 273:1705\u20131710","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"8809_CR18","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/bdd.1955","volume":"36","author":"G Moorthy","year":"2015","unstructured":"Moorthy G, Sallee F, Gabbita P, Zemlan F, Sallans L, Desai PB (2015) Safety, tolerability and pharmacokinetics of 2-pyridylacetic acid, a major metabolite of betahistine, in a phase 1 dose escalation study in subjects with ADHD. Biopharm Drug Dispos 36:429\u2013439","journal-title":"Biopharm Drug Dispos"},{"key":"8809_CR19","doi-asserted-by":"publisher","unstructured":"Murdin L, Hussain K, Schilder AG (2016) Betahistine for symptoms of vertigo. Cochrane Database Syst Rev CD010696. https:\/\/doi.org\/10.1002\/14651858.CD010696.pub2","DOI":"10.1002\/14651858.CD010696.pub2"},{"key":"8809_CR20","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1212\/WNL.42.2.339","volume":"42","author":"VV Myllyla","year":"1992","unstructured":"Myllyla VV, Sotaniemi KA, Vuorinen JA, Heinonen EH (1992) Selegiline as initial treatment in de novo parkinsonian patients. Neurology 42:339\u2013343","journal-title":"Neurology"},{"key":"8809_CR21","doi-asserted-by":"publisher","unstructured":"Phillips JS, Westerberg B (2011) Intratympanic steroids for Meni\u00e8re\u2019s disease or syndrome. Cochrane Database Syst Rev CD008514. https:\/\/doi.org\/10.1002\/14651858.CD008514.pub2","DOI":"10.1002\/14651858.CD008514.pub2"},{"key":"8809_CR22","first-page":"CD005395","volume":"2","author":"B Pullens","year":"2013","unstructured":"Pullens B, Verschuur HP, van Benthem PP (2013) Surgery for Meniere\u2019s disease. Cochrane Database Syst Rev 2:CD005395","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"8809_CR23","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/lary.26197","volume":"127","author":"FY Russo","year":"2017","unstructured":"Russo FY, Nguyen Y, De Seta D, Bouccara D, Sterkers O, Ferrary E, Bernardeschi D (2017) Meniett device in meniere disease: randomized, double-blind, placebo-controlled multicenter trial. Laryngoscope 127(2):470\u2013475. https:\/\/doi.org\/10.1002\/lary.26197","journal-title":"Laryngoscope"},{"key":"8809_CR24","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1258\/0022215053419871","volume":"119","author":"WK Smith","year":"2005","unstructured":"Smith WK, Sankar V, Pfleiderer AG (2005) A national survey amongst UK otolaryngologists regarding the treatment of Meniere\u2019s disease. J Laryngol Otol 119:102\u2013105","journal-title":"J Laryngol Otol"},{"key":"8809_CR25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0022-5347(24)07319-1","volume":"2","author":"LA Sternson","year":"1974","unstructured":"Sternson LA, Tobia AJ, Walsh GM, Sternson AW (1974) The metabolism of betahistine in the rat. Drug Metab Dispos 2:123\u2013128","journal-title":"Drug Metab Dispos"},{"key":"8809_CR26","first-page":"CD003599","volume":"3","author":"AS Thirlwall","year":"2006","unstructured":"Thirlwall AS, Kundu S (2006) Diuretics for Meniere\u2019s disease or syndrome. Cochrane Database Syst Rev 3:CD003599","journal-title":"Cochrane Database Syst Rev"}],"updated-by":[{"DOI":"10.1007\/s00415-020-09791-7","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T00:00:00Z","timestamp":1584489600000},"record-id":"22927"},{"DOI":"10.1007\/s00415-020-09791-7","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T00:00:00Z","timestamp":1584489600000}}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-018-8809-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-8809-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-8809-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T14:24:56Z","timestamp":1751466296000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-018-8809-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,12]]},"references-count":26,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["8809"],"URL":"https:\/\/doi.org\/10.1007\/s00415-018-8809-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,12]]},"assertion":[{"value":"29 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2020","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have retracted this article.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M Strupp is Joint Chief Editor of the Journal of Neurology, Editor in Chief of Frontiers of Neuro-otology and Section Editor of F1000. He has received speaker\u2019s honoraria from Abbott, Actelion, Auris Medical, Biogen, Eisai, GSK, Henning Pharma, Interacoustics, MSD, Otometrics, Pierre-Fabre, TEVA, UCB. He acts as a consultant for Abbott, Actelion, Auris Medical, Heel, IntraBio and Sensorion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This was an observational study with a small number of patients that did not require ethical approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard"}}]}}